Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Accumulated Expenses (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Accumulated Expenses for 12 consecutive years, with $6.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 61.66% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Sep 2025, down 61.66%, and an annual FY2024 reading of $12.3 million, up 51.2% over the prior year.
  • Accumulated Expenses was $6.4 million for Q3 2025 at CytomX Therapeutics, up from $4.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $34.2 million in Q4 2021 and bottomed at $3.8 million in Q1 2025.
  • Average Accumulated Expenses over 5 years is $14.6 million, with a median of $12.3 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses surged 309.42% in 2021, then plummeted 78.2% in 2024.
  • Year by year, Accumulated Expenses stood at $34.2 million in 2021, then decreased by 28.58% to $24.4 million in 2022, then crashed by 66.63% to $8.2 million in 2023, then soared by 51.2% to $12.3 million in 2024, then plummeted by 47.97% to $6.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for CTMX at $6.4 million in Q3 2025, $4.5 million in Q2 2025, and $3.8 million in Q1 2025.